AEG vs FHN

The Advanced Deterministic Scorecard reveals a Piotroski F-Score of 5/9, indicating stable but not strong financial health, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite a seemingly attractive valuation with a P/E of 8.47 well below sector average and a current price below the Graham Number of $11.87, earnings volatility is extreme—recent YoY EPS growth is -3075% and Q/Q EPS growth is -1170%, signaling severe deterioration. Dividend strength is solid at 70/100 with a 5.76% yield and sustainable 44.48% payout ratio, but insider sentiment is weak at 40/100 and technical trend is deeply bearish at 10/100. Combined with erratic earnings surprises averaging -745.99% over the last four quarters, the stock appears fundamentally deteriorating despite surface-level value appeal.

FHN presents a stark contrast between attractive valuation and deteriorating fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the current price of $24.21 is a discount to both the Graham Number ($28.16) and the growth-based Intrinsic Value ($58.7), the low health score and bearish insider activity suggest significant underlying risks. These concerns are partially offset by strong earnings growth (29.3% YoY) and a consistent track record of beating analyst estimates. Consequently, the stock is a high-risk value play where growth metrics clash with poor deterministic health indicators.